Shinji Hidaka - Chugai Pharmaceutical Director
| CHGCF Stock | USD 46.34 5.27 12.83% |
Director
Shinji Hidaka is Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit of Chugai Pharmaceutical Co since 2017.
| Tenure | 7 years |
| Phone | 81 3 3281 6611 |
| Web | https://www.chugai-pharm.co.jp |
Chugai Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Bonney | Bristol Myers Squibb | 61 | |
| Elizabeth Doherty | Novartis AG ADR | 64 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Phyllis Yale | Bristol Myers Squibb | 63 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Ton Buechner | Novartis AG ADR | 55 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| Graham Chipchase | AstraZeneca PLC ADR | 54 | |
| Ann Fudge | Novartis AG ADR | 70 | |
| Tony Mok | AstraZeneca PLC ADR | N/A | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Philip Broadley | AstraZeneca PLC ADR | 52 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
| Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
| Frans Houten | Novartis AG ADR | 61 | |
| Nancy Andrews | Novartis AG ADR | 63 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
| Srikant Datar | Novartis AG ADR | 67 | |
| Theodore Samuels | Bristol Myers Squibb | 66 | |
Management Performance
Chugai Pharmaceutical Leadership Team
Elected by the shareholders, the Chugai Pharmaceutical's board of directors comprises two types of representatives: Chugai Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chugai. The board's role is to monitor Chugai Pharmaceutical's management team and ensure that shareholders' interests are well served. Chugai Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chugai Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Junichi Ebihara, VP and General Manager of Legal Department | ||
| Toshiya Sasai, Exec Department | ||
| Shinji Hidaka, Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit | ||
| Osamu Okuda, Executive Officer, Director of Business Planning | ||
| Yoshiaki Ohashi, Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit | ||
| Tetsuya Yamaguchi, Executive Officer, Director of Business Development | ||
| Masahiko Uchida, Gen Department | ||
| Yoshiyuki Yano, Executive Officer, Director of Human Resources | ||
| Tsunanori Sato, Executive Officer, Chief Director of Sales | ||
| Toshiaki Itagaki, VP and General Manager of Fin. and Accounting Department |
Chugai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Chugai Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 39.67 B | |||
| Shares Outstanding | 1.64 B | |||
| Shares Owned By Insiders | 59.99 % | |||
| Shares Owned By Institutions | 18.71 % | |||
| Price To Earning | 19.49 X | |||
| Price To Book | 3.95 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Chugai Pink Sheet
Chugai Pharmaceutical financial ratios help investors to determine whether Chugai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Chugai with respect to the benefits of owning Chugai Pharmaceutical security.